Epigenetic biomarkers in Alzheimer's disease: Diagnostic and prognostic relevance
Ageing Research Reviews · 2024-12 · 102 · 102556
DOI: 10.1016/j.arr.2024.102556 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2024-12. Verfasst von Tapan Behl und 13 weiteren Autor:innen. Beteiligte Einrichtung: Amity School of Pharmaceutical Sciences, Amity University, Punjab 140306, India. Electronic address: tapanbehl31@gmail.com. Hauptthemen laut MEDLINE: Alzheimer Disease, Epigenesis, Genetic, Biomarkers, DNA Methylation. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 293 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a leading cause of cognitive decline in the aging population, presenting a critical need for early diagnosis and effective prognostic tools. Epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNAs, have emerged as promising biomarkers for AD due to their roles in regulating gene expression and potential for reversibility. This review examines the current landscape of epigenetic biomarkers in AD, emphasizing their diagnostic and prognostic relevance. DNA methylation patterns in genes such as APP, PSEN1, and PSEN2 are highlighted for their strong associations with AD pathology. Alterations in DNA methylation at specific CpG sites have been consistently observed in AD patients, suggesting their utility in early detection. Histone modifications, such as acetylation and methylation, also play a crucial role in chromatin remodelling and gene expression regulation in AD. Dysregulated histone acetylation and methylation have been linked to AD progression, making these modifications valuable biomarkers. Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), further contribute to the epigenetic regulation in AD. miRNAs can modulate gene expression post-transcriptionally and have been found in altered levels in AD, while lncRNAs can influence chromatin structure and gene expression. The presence of these non-coding RNAs in biofluids like blood and cerebrospinal fluid positions them as accessible and minimally invasive biomarkers. Technological advancements in detecting and quantifying epigenetic modifications have propelled the field forward. Techniques such as next-generation sequencing, bisulfite sequencing, and chromatin immunoprecipitation assays offer high sensitivity and specificity, enabling the detailed analysis of epigenetic changes in clinical samples. These tools are instrumental in translating epigenetic research into clinical practice. This review underscores the potential of epigenetic biomarkers to enhance the early diagnosis and prognosis of AD, paving the way for personalized therapeutic strategies and improved patient outcomes. The integration of these biomarkers into clinical workflows promises to revolutionize AD management, offering hope for better disease monitoring and intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amity School of Pharmaceutical Sciences, Amity University, Punjab 140306, India. Electronic address: tapanbehl31@gmail.com.
- Marwadi University Research Center, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Marwadi University, Rajkot, Gujarat 360003, India.
- Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of Pharmacy Practice, Institute of Pharmacy, NIMS University, Jaipur, India.
- Chandigarh Pharmacy College, Chandigarh Group of Colleges-Jhanjeri, Mohali, Punjab 140307, India.
- Department of Basic Science & Humanities, Raghu Engineering College, Visakhapatnam, India.
Zitieren
APA
Behl, T., Kyada, A., Roopashree, R., Nathiya, D., Arya, R., Kumar, M. R., Khalid, M., Gulati, M., Sachdeva, M., Fareed, M., Patra, P. K., Agrawal, A., Wal, P., & Gasmi, A. (2024). Epigenetic biomarkers in Alzheimer's disease: Diagnostic and prognostic relevance. Ageing Research Reviews, 102, 102556. https://doi.org/10.1016/j.arr.2024.102556
Vancouver
Behl T, Kyada A, Roopashree R, Nathiya D, Arya R, Kumar MR, et al. Epigenetic biomarkers in Alzheimer's disease: Diagnostic and prognostic relevance. Ageing Research Reviews. 2024;102:102556. doi:10.1016/j.arr.2024.102556
BibTeX
@article{Behl2024,
author = {Behl, Tapan and Kyada, Ashishkumar and Roopashree, R and Nathiya, Deepak and Arya, Renu and Kumar, M Ravi and Khalid, Mohammad and Gulati, Monica and Sachdeva, Monika and Fareed, Mohammad and Patra, Pratap Kumar and Agrawal, Ankur and Wal, Pranay and Gasmi, Amin},
title = {Epigenetic biomarkers in Alzheimer's disease: Diagnostic and prognostic relevance},
journal = {Ageing Research Reviews},
year = {2024},
volume = {102},
pages = {102556},
doi = {10.1016/j.arr.2024.102556}
}
EUVIMED